- Conditions
- Anxiety, Depression, Health Knowledge, Attitudes, Practice, Stigmatization, Mobile Phone Use
- Interventions
- Video Intervention 1, Video Intervention 2, Video Intervention 3
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1465–1488
of 85,874
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Fatigue
- Interventions
- DGB-01 Supplementation
- Dietary Supplement
- Lead sponsor
- William Black
- Other
- Eligibility
- 18 Years to 60 Years · Male only
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Rotator Cuff Tear, Rotator Cuff Injury, Rotator Cuff Tendinitis, Diabetes Mellitus
- Interventions
- Ketorolac, Triamcinolone Acetonide
- Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Oligodendroglioma, Astrocytoma, Grade II, Glioma, Astrocytic, Glioma, Malignant Glioma, Oligoastrocytoma, Mixed
- Interventions
- GBM6-AD and poly-ICLC before and after surgery, GBM6-AD and poly-ICLC after surgery only
- Biological
- Lead sponsor
- Jennie Taylor
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Brain Cancer, Brain Neoplasm, Primary, Brain Neoplasms, Recurrent, Brain Tumor, Cancer of the Brain
- Interventions
- PEPIDH1M vaccine, Tetanus-Diphtheria Toxoid (Td), Temozolomide
- Biological · Drug
- Lead sponsor
- Katy Peters, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- insulin degludec, placebo, liraglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 346 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 67
- States / cities
- Anaheim, California • Concord, California • Escondido, California + 59 more
- Conditions
- Healthy
- Interventions
- Control Volunteers, Clinical Volunteers
- Other
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Multiple Myeloma
- Interventions
- Cevostamab, Pomalidomide, Dexamethasone, Daratumumab, Elotuzumab, Carfilzomib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 380 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 10
- States / cities
- Duarte, California • Irvine, California • New Haven, Connecticut + 7 more
- Conditions
- Small Cell Lung Cancer
- Interventions
- Not listed
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 2
- States / cities
- Kansas City, Kansas • Omaha, Nebraska
- Conditions
- Atopic Dermatitis
- Interventions
- Combination of pimecrolimus and fluticasone, pimecrolimus
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 2 Years to 65 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Chicago, Illinois • Houston, Texas
- Conditions
- Anemia in Pregnancy, Preeclampsia
- Interventions
- Neevo® (a medical food), Prenatal vitamins (≤1mg folic acid, 27 - 35mg iron, and ≤12mcg vitamin B12)
- Other
- Lead sponsor
- Pamlab, Inc.
- Industry
- Eligibility
- 21 Years to 39 Years · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 3
- States / cities
- Sheffield, Alabama • Flowood, Mississippi • Gainesville, Texas
- Conditions
- Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Breast Cancer, HER2-negative Breast Cancer, Germline BRCA1 Gene Mutation, Germline BRCA2 Gene Mutation, Deleterious PALB2 Gene Mutation
- Interventions
- Niraparib, Dostarlimab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 8
- States / cities
- New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 3 more
- Conditions
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- Interventions
- Palbociclib + Letrozole or Fulvestrant
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 6
- States / cities
- Washington D.C., District of Columbia • Chicago, Illinois • Baltimore, Maryland + 1 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Lab Work, Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg), Certolizumab pegol (CDP870, tradename Cimzia), Hydroxychloroquine, Sulfasalazine, Medrol, Prednisone, Triamcinolone, Naproxen, Leflunomide, Methotrexate, humira
- Other · Drug
- Lead sponsor
- University of Illinois Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Sarcoma, Synovial Sarcoma, Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor
- Interventions
- Sorafenib and Dacarbazine
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Tracheobronchomalacia, Tracheal Stenosis
- Interventions
- Not listed
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Spinal Cord Injury
- Interventions
- Baclofen
- Drug
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 20 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2011
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Placebo - Control, Ketone Monoester
- Interventions
- Ketone Monoester (KE), Placebo
- Dietary Supplement
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years to 55 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Non-adaptive Floreo VR control, Floreo Virtual Reality application
- Behavioral
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 8 Years to 16 Years
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7
- Interventions
- Falimarev, Inalimarev, Laboratory Biomarker Analysis, Sargramostim
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2027
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Borderline Personality Disorder, Suicide
- Interventions
- Fluoxetine, DBT, Citalopram
- Drug · Behavioral
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Vomiting, Nausea, Nausea and Vomiting, Chemotherapy-Induced
- Interventions
- Casopitant (GW679769) oral tablets, Casopitant (GW679769) intravenous, Dexamethasone intravenous, Ondansetron oral tablets, placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,840 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 86
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Fayetteville, Arkansas + 78 more
- Conditions
- Gastroenteritis Escherichia Coli, Immunisation
- Interventions
- Placebo, Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
- Other · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Type 1 Diabetes, Celiac Disease
- Interventions
- Combined Risk Score
- Diagnostic Test
- Lead sponsor
- Pacific Northwest Research Institute
- Other
- Eligibility
- 1 Day to 7 Years
- Enrollment
- 64,410 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Seattle, Washington